Preclinical and first-in-human-brain-cancer applications of [¹⁸F]poly (ADP-ribose) polymerase inhibitor PET/MR.

ABSTRACT:

Background

We report preclinical and first-in-human-brain-cancer data using a targeted poly (ADP-ribose) polymerase 1 (PARP1) binding PET tracer, [¹⁸F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment-related changes.

Methods

We applied a glioma model in p53-deficient nestin/tv-a mice, which were injected with [¹⁸F]PARPi and then sacrificed 1 h post-injection for brain examination. We also prospectively enrolled patients with brain cancers to undergo dynamic [¹⁸F]PARPi acquisition on a dedicated positron emission tomography/magnetic resonance (PET/MR) scanner. Lesion diagnosis was established by pathology when available or by Response Assessment in Neuro-Oncology (RANO) or RANO-BM response criteria. Resected tis

SUBMITTER: Young RJ 

PROVIDER: S-EPMC7758909 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature